Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kiniksa Pharmaceuticals International, plc KNSA

Healthcare  —  Drug Manufacturers Specialty & Generic
75.08 (0.26) (0.35%) as of 25 Sep
Market cap
$5.9B
P/E
70.2×
Cash Flow Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Revenue 840.85 754.05 677.56 597.97

+8 more TTM periods
Cost of Revenue 85.57 80.60 77.67 74.62
Gross Profit 755.28 673.44 599.89 523.35
R&D Expenses 127.15 105.00 96.85 97.46
SG&A Expenses 230.90 213.89 196.27 180.03
Operating Income 100.25 93.22 77.22 38.15
Non-operating Income/Expense 14.00 12.77 11.65 10.47
EBT 114.25 105.98 88.87 48.62
Income Tax Provision 33.59 32.93 29.86 12.70
Income after Tax 80.66 73.06 59.01 35.92
Net Income Common 80.66 73.06 59.01 35.92
EPS (Basic) 1.07 0.98 0.80 0.49
Gross Margin 89.82% 89.31% 88.54% 87.52%
EBIT Margin 11.92% 12.36% 11.40% 6.38%
EBT margin 13.59% 14.06% 13.12% 8.13%
Net Profit Margin 9.59% 9.69% 8.71% 6.01%
Free Cash Flow Margin 21.74% 21.78% 20.13% 17.01%
EBITDA 102.04 94.89 78.78 39.64
EBIT 100.25 93.22 77.22 38.15
EPS (Diluted, from Cont. Ops) 0.99 0.91 0.75 0.45
EPS (Basic, Consolidated) 1.06 0.97 0.80 0.48
EPS (Basic, from Continuous Ops) 1.06 0.97 0.80 0.48
Income from Continuous Operations 80.66 73.06 59.01 35.92
Consolidated Net Income/Loss 80.66 73.06 59.01 35.92
EBITDA Margin 12.14% 12.58% 11.63% 6.63%
Operating Cash Flow Margin 22.00% 22.00% 20.36% 17.20%

Fold the line items

In millions of $ except per-share values · columns are period end dates